InnovAge (NASDAQ:INNV – Get Free Report) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Monday, Zacks reports.
A number of other research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of InnovAge from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. Weiss Ratings upgraded InnovAge from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, November 4th. Finally, KeyCorp lifted their price target on InnovAge from $13.00 to $14.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, InnovAge presently has an average rating of “Moderate Buy” and a consensus price target of $10.50.
Read Our Latest Report on InnovAge
InnovAge Price Performance
Shares of INNV stock opened at $9.42 on Monday. InnovAge has a fifty-two week low of $4.70 and a fifty-two week high of $12.64. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.16 and a current ratio of 1.16. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of 159.67 and a beta of 0.16. The stock’s 50-day simple moving average is $9.46 and its 200-day simple moving average is $9.25.
InnovAge (NASDAQ:INNV – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $264.76 million during the quarter, compared to analyst estimates of $257.23 million. InnovAge had a net margin of 0.88% and a return on equity of 3.63%. As a group, equities analysts forecast that InnovAge will post 0.44 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, major shareholder Carson Anderson & Stow Welsh sold 1,500,000 shares of the business’s stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $9.25, for a total transaction of $13,875,000.00. Following the completion of the transaction, the insider directly owned 101,076,555 shares in the company, valued at $934,958,133.75. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Nicole Damato sold 23,814 shares of the company’s stock in a transaction on Friday, September 25th. The shares were sold at an average price of $8.70, for a total transaction of $207,181.80. Following the completion of the sale, the insider directly owned 304,897 shares in the company, valued at approximately $2,652,603.90. The trade was a 7.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,027,216 shares of company stock valued at $120,489,535 over the last 90 days. Insiders own 1.10% of the company’s stock.
Hedge Funds Weigh In On InnovAge
Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in InnovAge during the second quarter valued at approximately $17,652,000. Algert Global LLC boosted its position in InnovAge by 844.1% in the 2nd quarter. Algert Global LLC now owns 630,520 shares of the company’s stock worth $7,472,000 after purchasing an additional 563,735 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in InnovAge by 207.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 668,219 shares of the company’s stock worth $5,880,000 after purchasing an additional 450,610 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of InnovAge during the 1st quarter worth approximately $3,349,000. Finally, Marshall Wace LLP acquired a new stake in shares of InnovAge during the 3rd quarter worth approximately $3,589,000. Institutional investors and hedge funds own 12.26% of the company’s stock.
About InnovAge
InnovAge, Inc. provides integrated healthcare and social services to older adults through the Program of All-Inclusive Care for the Elderly (PACE). The program serves people who qualify for nursing-home-level care but can continue living in their communities with coordinated support. InnovAge’s services include primary and specialty care coordination, nursing, rehabilitation, social services, prescription medications, transportation, in-home assistance and adult day health services. Care is coordinated by interdisciplinary teams and delivered through a combination of community-based centers and support at home.
See Also
- Five stocks we like better than InnovAge
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for InnovAge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnovAge and related companies with MarketBeat.com's FREE daily email newsletter.
